Subscribe for the latest updates Email* Subscribe Thank you for subscribing! A confirmation email has been sent to your email address. Please follow the link to confirm your subscription Filter news by date Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Year Year20192018201720162015201420132012201120102009200820072006 Apply Galderma marks Rosacea Awareness Month with new insights into why some patients are self-treating and launches social media campaign to reinforce hidden impact of the disease Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines Nestlé Skin Health SHIELD Hosts Skin Microbiome Summit Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting Late-Breaking Session Galderma: New data reveals benefits of combining oral and topical treatment in patients with severe papulopustular rosacea Galderma Announces Publication of Pivotal Phase 3 PERFECT 1 and PERFECT 2 Clinical Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne in the Journal of the American Academy of Dermatology Galderma Announces Formation of Women in Aesthetics Leadership Council Nestlé Skin Health Opens Office in Malaysia International Dermatology Community Voting for the 2018 Galderma SKINPACT Awards Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis Women-Focused Biotech Takes Top Prize at Nestlé Skin Health SHIELD Pitch Event Galderma U.S. Initiates Six New Studies, Increasing Company's Commitment to Aesthetic Research and Innovation Pagination Next page Next
Galderma marks Rosacea Awareness Month with new insights into why some patients are self-treating and launches social media campaign to reinforce hidden impact of the disease
Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting Late-Breaking Session
Galderma: New data reveals benefits of combining oral and topical treatment in patients with severe papulopustular rosacea
Galderma Announces Publication of Pivotal Phase 3 PERFECT 1 and PERFECT 2 Clinical Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne in the Journal of the American Academy of Dermatology
Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Galderma U.S. Initiates Six New Studies, Increasing Company's Commitment to Aesthetic Research and Innovation
